{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:21:11Z","timestamp":1787610071576,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Germline mutations in high-risk genes, such as\n                    <jats:italic>BRCA1<\/jats:italic>\n                    and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    , are primarily responsible for inherited breast cancers, while mutations in moderate-risk genes also increase susceptibility.\n                    <jats:italic>HOXB13<\/jats:italic>\n                    is established as a high-risk gene for prostate cancer (PCa), but few studies have explored its role in breast cancer. Here, we report, for the first time, novel\n                    <jats:italic>HOXB13<\/jats:italic>\n                    variants identified in breast cancer patients, suggesting a potential association that warrants further investigation. This retrospective cohort study was conducted at the Medical Genetics Laboratory of G\u00f6ztepe Prof. Dr. S\u00fcleyman Yal\u00e7\u0131n City Hospital, Turkey, between 2022 and 2025. A total of 4198 individuals who underwent hereditary cancer panel testing were screened. Targeted next-generation sequencing was performed using a Custom Hereditary Cancer (cHCS) panel on the Illumina NextSeq\u00ae platform. Raw sequencing data were analyzed using Dragen v3.6 and Sophia DDM pipelines. Among 4198 individuals, 1527 had a confirmed breast cancer diagnosis. Eleven patients harbored variants of uncertain significance (VUS) in\n                    <jats:italic>HOXB13<\/jats:italic>\n                    . Hormone-negative patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093) carried c.269del, c.766\u2009T\u2009&gt;\u2009C, and c.309_311del variants. Among hormone-positive patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098), two carried c.309_311del, one had c.404\u2009G\u2009&gt;\u2009A, and five carried c.728\u2009A\u2009&gt;\u2009G (p.K243R), the most frequent variant in this subgroup. The\n                    <jats:italic>HOXB13<\/jats:italic>\n                    variant spectrum in the Turkish population differed from previously reported data. Novel\n                    <jats:italic>HOXB13<\/jats:italic>\n                    variants, particularly c.728\u2009A\u2009&gt;\u2009G (p.K243R), may represent candidate variants of interest that require further validation before any clinical application. These findings highlight a potential association between\n                    <jats:italic>HOXB13<\/jats:italic>\n                    variants and breast cancer, particularly in hormone receptor-positive patients, and emphasize the need for larger and functionally validated studies.\n                  <\/jats:p>","DOI":"10.1038\/s10038-026-01481-y","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:18:20Z","timestamp":1779427100000},"page":"565-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HOXB13, a high-risk prostate cancer gene, also confers risk for breast cancer: novel variants of clinical significance, especially in hormone-positive patients"],"prefix":"10.1038","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-5387","authenticated-orcid":false,"given":"Filiz","family":"Ozen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4637-0253","authenticated-orcid":false,"given":"Zeynep","family":"Yegin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0903-3199","authenticated-orcid":false,"given":"Diyar","family":"Sayit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1481_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10549-012-2295-y","volume":"136","author":"MR Akbari","year":"2012","unstructured":"Akbari MR, Klu\u017aniak W, Rodin R, Li S, Woko\u0142orczyk D, Royer R, et al. The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer. Breast Cancer Res Treat. 2012;136:907\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"1481_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/srep30026","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Prager-van der Smissen WJ, Schmidt MK, Coll\u00e9e JM, Cornelissen S, Lamping R, et al. Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk. Sci Rep. 2016;6:30026.","journal-title":"Sci Rep"},{"key":"1481_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65665-y","volume":"10","author":"J Liu","year":"2020","unstructured":"Liu J, Prager-van der Smissen WJC, Coll\u00e9e JM, Bolla MK, Wang Q, Michailidou K, et al. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020;10:9688.","journal-title":"Sci Rep"},{"key":"1481_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1055-9965.EPI-15-0247","volume":"24","author":"JL Beebe-Dimmer","year":"2015","unstructured":"Beebe-Dimmer JL, Hathcock M, Yee C, Okoth LA, Ewing CM, Isaacs WB, et al. The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. Cancer Epidemiol Biomark Prev. 2015;24:1366\u201372.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1481_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/pros.22552","volume":"73","author":"X Lin","year":"2013","unstructured":"Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013;73:169\u201375.","journal-title":"Prostate"},{"key":"1481_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141\u20139.","journal-title":"N Engl J Med"},{"key":"1481_CR7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1158\/1055-9965.EPI-12-0495","volume":"21","author":"JP Breyer","year":"2012","unstructured":"Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomark Prev. 2012;21:1348\u201353.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1481_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","volume":"65","author":"R Karlsson","year":"2014","unstructured":"Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2014;65:169\u201376.","journal-title":"Eur Urol"},{"key":"1481_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/annonc\/mdv004","volume":"26","author":"Z Kote-Jarai","year":"2015","unstructured":"Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol. 2015;26:756\u201361.","journal-title":"Ann Oncol"},{"key":"1481_CR10","first-page":"97","volume":"32","author":"R Roudi","year":"2018","unstructured":"Roudi R, Nemati H, Rastegar Moghadam M, Sotoudeh M, Narouie B, Shojaei A. Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population. Med J Islam Repub Iran. 2018;32:97.","journal-title":"Med J Islam Repub Iran"},{"key":"1481_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bju.12522","volume":"113","author":"JL Beebe-Dimmer","year":"2014","unstructured":"Beebe-Dimmer JL, Isaacs WB, Zuhlke KA, Yee C, Walsh PC, Isaacs SD, et al. Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. BJU Int. 2014;113:830\u20135.","journal-title":"BJU Int"},{"key":"1481_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.canep.2013.03.003","volume":"37","author":"MR Akbari","year":"2013","unstructured":"Akbari MR, Anderson LN, Buchanan DD, Clendenning M, Jenkins MA, Win AK, et al. Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer. Cancer Epidemiol. 2013;37:424\u20137.","journal-title":"Cancer Epidemiol"},{"key":"1481_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-007-9541-8","volume":"107","author":"PL Jerevall","year":"2008","unstructured":"Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmstr\u00f6m P, Nordenskj\u00f6ld B, et al. Exploring the two-gene ratio in breast cancer\u2013independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat. 2008;107:225\u201334.","journal-title":"Breast Cancer Res Treat"},{"key":"1481_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1056\/NEJMc1205138","volume":"367","author":"S Alanee","year":"2012","unstructured":"Alanee S, Couch F, Offit K. Association of a HOXB13 variant with breast cancer. N Engl J Med. 2012;367:480\u20131.","journal-title":"N Engl J Med"},{"key":"1481_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"1481_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/pros.23453","volume":"78","author":"H Chen","year":"2018","unstructured":"Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, et al. Genetic factors influencing prostate cancer risk in Norwegian men. Prostate. 2018;78:186\u201392.","journal-title":"Prostate"},{"key":"1481_CR17","doi-asserted-by":"publisher","first-page":"e0164233","DOI":"10.1371\/journal.pone.0164233","volume":"11","author":"T Hayano","year":"2016","unstructured":"Hayano T, Matsui H, Nakaoka H, Ohtake N, Hosomichi K, Suzuki K, et al. Germline Variants of Prostate Cancer in Japanese Families. PLoS One. 2016;11:e0164233.","journal-title":"PLoS One"},{"key":"1481_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/jnci\/djz124","volume":"112","author":"Y Momozawa","year":"2020","unstructured":"Momozawa Y, Iwasaki Y, Hirata M, Liu X, Kamatani Y, Takahashi A, et al. Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12366 Controls. J Natl Cancer Inst. 2020;112:369\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"1481_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4111\/icu.20220044","volume":"63","author":"MK So","year":"2022","unstructured":"So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022;63:294\u2013300.","journal-title":"Investig Clin Urol"},{"key":"1481_CR20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2021.12.023","volume":"81","author":"BF Darst","year":"2022","unstructured":"Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, et al. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur Urol. 2022;81:458\u201362.","journal-title":"Eur Urol"},{"key":"1481_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41416-021-01622-4","volume":"126","author":"R Na","year":"2022","unstructured":"Na R, Wei J, Sample CJ, Gielzak M, Choi S, Cooney KA, et al. The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. Br J Cancer. 2022;126:791\u20136.","journal-title":"Br J Cancer"},{"key":"1481_CR22","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-05-1263","volume":"12","author":"MP Goetz","year":"2006","unstructured":"Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006;12:2080\u20137.","journal-title":"Clin Cancer Res"},{"key":"1481_CR23","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1158\/1078-0432.CCR-08-0619","volume":"14","author":"MP Goetz","year":"2008","unstructured":"Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, et al. Cytochrome P450 2D6 and homeobox 13\/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res. 2008;14:5864\u20138.","journal-title":"Clin Cancer Res"},{"key":"1481_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3402","volume":"15","author":"LA Habel","year":"2013","unstructured":"Habel LA, Sakoda LC, Achacoso N, Ma XJ, Erlander MG, Sgroi DC, et al. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 2013;15:R24.","journal-title":"Breast Cancer Res"}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s10038-026-01481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-026-01481-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s10038-026-01481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:03:19Z","timestamp":1787608999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s10038-026-01481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1038\/s10038-026-01481-y","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}